Skip to content

Wegovy

Also called semaglutide 2.4 mg, Wegovy pen, weight-loss semaglutide.

By Dr Chad Okay4 min read

Wegovy is a brand name for semaglutide injections licensed for weight loss in adults with obesity or overweight with weight-related health conditions. It is the same drug as Ozempic but at a higher weekly dose of up to 2.4 mg. It works by mimicking the gut hormone GLP-1, which lowers appetite and slows stomach emptying.

What Wegovy is and is not

Wegovy is semaglutide, the same molecule sold as Ozempic for type 2 diabetes. It is licensed at higher doses (up to 2.4 mg weekly) specifically for weight management. NICE recommends it on the NHS for adults with a body mass index (BMI) of at least 35 plus a weight-related condition, accessed through specialist weight-management services. Most UK users currently pay privately.

How it works

Semaglutide activates GLP-1 receptors in the brain and gut. Three things happen at once: stomach emptying slows so food sits longer and you feel full sooner, the brain registers fullness at a lower food volume, and craving signals between meals quiet down. Average weight loss in the STEP trials was about 15% of body weight at 68 weeks, against around 2.4% on placebo.

The dose ladder

  1. Week 1 to 4: 0.25 mg weekly. Starter dose, mostly for tolerance.
  2. Week 5 to 8: 0.5 mg weekly. Mild appetite suppression begins.
  3. Week 9 to 12: 1.0 mg weekly. Most people notice meaningful changes here.
  4. Week 13 to 16: 1.7 mg weekly. Bigger appetite drop, side effects often peak briefly.
  5. Week 17 onwards: 2.4 mg weekly. The full maintenance dose.

Side effects to expect

  • Nausea: very common in the first 8 weeks and after each dose increase. Usually settles within a fortnight.
  • Constipation: common (around 24% on 2.4 mg vs around 11% on placebo in the pooled STEP trials, Wharton 2022) because gut transit is genuinely slowed. Daily fluid, fibre and movement matter more than usual.
  • Reflux and burping: stomach contents linger, pressure builds.
  • Tiredness and headache: often related to the lower calorie intake itself, not the drug directly.
  • Hair shedding: reported by a meaningful minority. Linked to rapid weight loss and lower protein intake, usually reversible.
  • Rare but serious: pancreatitis, gallstones, severe gastroparesis. Severe, persistent abdominal pain needs a doctor the same day, not a wait-and-see approach (see below).

If something feels wrong

This entry is reference information, not medical guidance. Your doctor and pharmacist know you and your medicine; if anything about how you feel worries you, speak to them promptly, and if you ever feel seriously unwell, treat it as an emergency. The medicine's own patient information leaflet carries the important safety information and is worth reading in full.

What happens after you stop

Two thirds of weight lost is regained within a year of stopping in trial extensions. Appetite signalling returns to baseline within weeks. Most weight-management specialists treat Wegovy as a long-term medication rather than a course of treatment. The economic question this raises is real and unresolved.

Common questions

Available in principle but rationed in practice. NICE TA875 recommends it only within a specialist weight-management service, for a maximum of 2 years, for adults with at least one weight-related condition and a BMI of 35 or more, or 30 to 34.9 if they meet specialist referral criteria, with lower thresholds (usually reduced by 2.5) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds. The number of those services is limited, so most UK users currently pay privately.

Built for this.

Suna is a wearable designed to help you see your own everyday patterns, without keeping a diary. Reservations open.

Sources

  1. 1Wegovy 2.4 mg FlexTouch summary of product characteristics (posology and dose escalation)EMC (UK)
  2. 2NICE TA875: semaglutide for managing overweight and obesity, RecommendationsNICE
  3. 3STEP 1 trial: Wilding et al 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM, PMID 33567185)New England Journal of Medicine
  4. 4STEP 1 trial extension: Wilding et al 2022, weight regain after withdrawal of semaglutide (Diabetes Obesity and Metabolism)Diabetes, Obesity and Metabolism
  5. 5Wharton et al 2022, Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg (pooled STEP trials, PMID 34514682)Diabetes, Obesity and Metabolism
  6. 6STEP 5 trial: Garvey et al 2022, two-year effects of semaglutide (Nature Medicine, PMC9556320)Nature Medicine
  7. 7Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period (2024)Clinical Gastroenterology and Hepatology
Written by Dr Chad Okay. Contributor: Dr Parisah Hussain, MBChB, BSc (Hons), DRCOG, MRCGP. Last updated . From Digests.

Related reading

All Digests

About Digests

Digests explains how the body works in general, everyday terms. It is not medical advice. It is not a substitute for someone who can examine you and knows your history, and we do not tell you what dose of any medicine to take.

Where we describe how something is checked or looked after, we follow UK guidance from NICE and the NHS, so the tests and routes where you live may differ. The same concerns are worth taking to your own doctor.

Some articles explain approaches that researchers have studied, including gut-directed hypnotherapy. Explaining an approach is education, not an offer of it: Suna does not provide hypnotherapy or any medical or psychological treatment.

Suna Health is building a wearable wellness device for gut health and offers a gut-directed relaxation app, and you will see both advertised alongside these pages. That commercial interest does not decide what the content says.

If you think we have got something wrong, tell us at digests@suna.health. It goes to the editor. Full terms, including our liability position, are at suna.health/terms.

The wearable for gut health and nutrition. Built by a passionate team, grounded in peer-reviewed research.

Suna

Suna is a wellness device, not a medical or diagnostic device. It does not diagnose, treat, cure, or prevent any disease. The Suna app offers a five-week gut-directed relaxation program for general wellbeing. The program is a self-guided wellness practice: it is not medical care, not psychological treatment, and not hypnotherapy, and it is not a substitute for care from a qualified practitioner. Information provided is general wellness information, not medical advice. Always consult a qualified healthcare professional about any health concern.

Suna Health US, Inc., 2810 N Church St STE 90849, Wilmington, DE 19802

© 2026 Suna Health.